C ystic fibrosis is the most common, life-shortening, autosomal recessive genetic disease among whites. 1 Approximately 35,000 children and adults have cystic fibrosis in the United States (US), with worldwide prevalence estimated in more than 70,000 individuals. 2, 3 Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator gene. Cystic fibrosis impacts multiple organ systems, including respiratory and gastrointestinal. 4 Because of advances in disease management, detection, and therapy, survival has increased in individuals with cystic fibrosis. The median predicted survival age increased from 33.3 to 41.7 years between 2000 and 2015, and currently more than half of individuals with cystic fibrosis are aged 18 or older. 4 However, with improved survival, individuals with cystic fibrosis increasingly become at risk for other diseases that typically occur at older ages, especially those involving the gastrointestinal tract. 5 Gastrointestinal malignancies are an emerging health problem among individuals with cystic fibrosis. Several studies have shown an increased risk of digestive tract cancers and an increased early incidence and progression of adenomatous colorectal polyps to colorectal cancer (CRC). [5] [6] [7] [8] Screening for CRC is a well-established intervention that has been shown to reduce the burden of CRC in the general population. [9] [10] [11] [12] [13] [14] [15] [16] [17] Screening generally starts at the age of 50 for the average risk population, with those at higher risk (such as those with family history of CRC [first-degree relatives] or Lynch syndrome) commencing at an earlier age. 18 Although those with cystic fibrosis fall into the latter category (their CRC risk exceeds that of those with first-degree relatives), their lower life expectancy may lead to a different trade-off between the benefits and harms of CRC screening. At present, there are no specific recommendations for screening and surveillance for this population.
We performed a decision analysis for the Cystic Fibrosis Foundation and Cystic Fibrosis CRC Screening Task Force, 19 to explore the benefits, harms, and costs of CRC screening in the CF population and determine the most appropriate CRC screening strategy using a modeling approach.
and the age-specific prevalence distribution of adenomas seen in autopsy studies (Supplementary Figure 2) . [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Adenoma dwell time and the preclinical duration of CRC were calibrated to the outcomes of the randomized clinical trials evaluating screening using guaiac fecal occult blood tests and sigmoidoscopy.
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Adaptions of the MISCAN-Colon Model to the Cystic Fibrosis Population
The MISCAN-Colon model was adjusted to reflect the increased CRC risk and the elevated all-cause mortality in individuals with cystic fibrosis. Modeling was performed separately for individuals who never received a transplant and those who were post-transplant to account for differences in CRC risk and survival between these 2 groups (non-transplant vs transplant patients). We assumed that the higher CRC risk in both groups was caused by a more frequent adenoma onset (increased probability of adenoma occurrence across all ages), which would result in more CRC.
For individuals with cystic fibrosis who have not had a transplant, the parameters of the model were adjusted to replicate the 7-fold higher CRC risk observed in a 20-year study of 48,188 individuals with cystic fibrosis included in the Cystic Fibrosis Foundation Patient Registry (Figure 1) . 6 Adenoma and advanced adenoma (ie, large adenoma 10 mm) detection rates at 2 different screening rounds were computed and compared with the adenoma detection rates observed in an observational study of people with cystic fibrosis undergoing colonoscopy screening (Supplementary Figure 3) . 8 The model was also adjusted to reflect the overall mortality of individuals with cystic fibrosis in 2015. 4 In all analyses for cystic fibrosis transplant patients, we assumed the same adenoma risk as the non-transplant cystic fibrosis population until organ transplantation. We assumed a more frequent onset of adenomas immediately after organ transplant. A 30-fold increase in CRC risk was based on the US cohort study by Maisonneuve et al 6 ( Figure 1 ). Simulated adenoma and advanced adenoma detection rates were computed and are reported in Supplementary Figure 3 . In addition to a higher CRC risk, we also assumed that transplanted individuals with cystic fibrosis had a higher risk of dying of CRC once diagnosed. The increased CRC death-specific risk was modeled as a hazard ratio of 2 based on the excess risk of CRC death using the model provided by Rutter et al. 22 Life expectancy post transplantation was based on life tables for individuals with cystic fibrosis after lung transplantation. Lung transplants constitute 90% of transplantations in individuals with cystic fibrosis. 4 Our model reflected the International Society for Heart and Lung Transplantation's data, which shows that for individuals with cystic fibrosis post-transplant survival is related to time since the transplant and not age. 35 We simulated this entire population with transplant at the age of 30 years (the median age of transplant) and assessed earlier ages of transplantation in sensitivity analyses to assess if the optimal screening strategies would change.
Screening Strategies Simulated
For both groups (transplant and non-transplant individuals with cystic fibrosis), a cohort of 10 million individuals, aged 30 years in 2017, was simulated with the adjusted MISCAN-Colon model under 76 different colonoscopy screening strategies (a total of 152 different screening strategies). The strategies differed with respect to (i) screening interval (3, 5, or 10 years for colonoscopy; (ii) age to start (30, 35, 40, 45, 50 years) ; and (iii) age to end screening (55, 60, 65, 70, 75 years). Furthermore, an additional cohort of 10 million individuals aged 30 years in 2017 without cystic fibrosis was simulated to enable a
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comparison of outcomes between the cystic fibrosis population and the US general population under the recommended US CRC screening guidelines (colonoscopy starting at age 50, repeated every 10 years).
In addition, given that colonoscopy might be very demanding for individuals with cystic fibrosis, we explored the fecal immunochemical test (FIT) as a possible and hypothetically adequate alternative in this population. As such, we performed a specific supplementary analysis including also annual FIT screening (25 screening strategies).
Screening Assumptions
Test characteristics and complication rates for each screening test were based on studies in the general population (Supplementary Table 1) 36-40 because specific information for the cystic fibrosis population is not available.
Modeling FIT screening strategies, we assumed that patients with a positive FIT result were referred for a diagnostic colonoscopy (positive threshold: 100 ng/ml buffer, equals to 20 mg/g feces).
37 Individuals with adenomas detected and removed during a screening or diagnostic colonoscopy were assumed to enter colonoscopy surveillance according to the current general population guidelines, 18 except for colonoscopy screening strategies with 3-year screening interval where a more intensive colonoscopy surveillance interval was introduced in line with the screening interval: every 3 years. We assumed 100% adherence to screening, diagnostic, and surveillance tests.
Because it is reasonable to consider that the performance of CRC screening in the cystic fibrosis population may be different with regards to colonoscopy complications, adverse events related to a more intensive bowel preparation, and the efficacy of FIT, we address these aspects in specific sensitivity analyses to assess if the optimal screening strategies would be affected.
CRC Screening Costs and Outcomes
The cost-effectiveness analyses were carried out from a societal perspective. The costs of screening tests were based on the 2014 Medicare payment rates including co-payments (Supplementary Table 2 ). Complication costs were obtained from a cost analysis study of cases hospitalized after endoscopy in 2007. 41 Patient time costs were added to both. 42 The cost of life-years with CRC care were based on the SEER-Medicare linked data analysis and included co-payments and patient time costs. 43 All costs were adjusted to 2015 using the annual average Consumer Price Indexes provided by the US Bureau of Labor Statistics. 44 For each simulated cohort, we computed the effectiveness (ie, CRC cases prevented, CRC deaths prevented, and life-years gained [LYG] ) and costs of the screening. LYG from screening and costs were discounted by applying the conventional 3% annual discount rate.
Cost-effectiveness Analyses
We determined the cost-effectiveness of each screening strategy and compared these results with no screening. Subsequently, we performed an incremental cost-effectiveness analysis to determine the optimal screening strategy. To do this we: (i) ranked all the screening strategies by increasing costs; (ii) excluded all the screening strategies that were more costly and less effective than other strategies ("strongly dominated strategies"); (iii) deleted the screening strategies that were less costly and less effective than another but provided an additional life-year at higher incremental costs ("weakly dominated strategies"); (iv) calculated for all remaining strategies ("efficient strategies," or strategies on the "efficient frontier") the incremental cost-effectiveness ratio (ICER) as the ratio between additional costs and additional clinical benefits (in this case, LYG) of a specific screening strategy compared with the previous less expensive strategy (ie, strategy with costs lower and closest to the strategy of interest); and (v) selected the optimal strategy assuming a willingness to pay threshold of $100,000 per LYG.
Sensitivity Analyses
We conducted multiple sensitivity analyses to test the robustness of the model results under a variety of different assumptions. These assumptions included: (i) lowering colonoscopy test sensitivity for small and medium size adenomas (0.65 and 0.80, respectively); (ii) a more proximal CRC location (50% of CRC in the right colon); (iii) increasing colonoscopy complication rates 2-fold; (iv) increasing the risk of cardiovascular complications associated with colonoscopy (5-and 10-fold increased risk, including respiratory arrest); (v) lowering FIT specificity (0.90); (vi) a worst case for FIT considering a lower specificity (0.75) and sensitivity (ie, 36% reduced) in cystic fibrosis population (different FIT performances); (vii) biennial screening intervals for FIT; (viii) lowering adherence to the screening test (80%); (ix) more intensive colonoscopy surveillance (3 years) for all the screening strategies; and (x) increasing costs because of increased patient time (Supplementary Table 2 ). Maisonneuve et al. 2013 and CRC incidence simulated in the MISCAN-Colon model without screening in the US general population, non-transplant, and transplant cystic fibrosis patients assuming a higher CRC risk through a more frequent adenoma onset (base case analysis). Note: Bars indicate 95% confidence intervals; CRC, colorectal cancer; CF, cystic fibrosis.
Additionally, among the non-transplant people with cystic fibrosis, we analyzed the impact of: (i) a higher CRC risk (10-fold increased risk compared with general population); (ii) a higher CRC risk (7-fold) because of a shorter adenoma dwell time (94% reduced, extremely fast adenoma progression) instead of a more frequent adenoma onset (Supplementary Figure 4) ; and (iii) a higher all-cause mortality in older ages ( 45 years) . 45 For the individuals with cystic fibrosis who have had a transplant, we investigated the impact of: (i) differential age at transplant (20 and 25 years old in 2017); (ii) additional colonoscopy screening strategies (starting at age 32, every 5 years); (iii) increased CRC risk (45-fold increased risk) with a more proximal CRC location (50% of CRC in the right colon); (iv) utilization of the same age-specific mortality rate observed among non-transplant individuals with cystic fibrosis after age 50 years; and (v) higher CRC risk because of a combination of shorter adenoma dwell time (50% reduced) and higher adenoma onset (16-fold increased risk calibrated to replicate the increased CRC incidence among these individuals; Supplementary Figure 4) .
Results
Without screening, the model predicted 19.1 CRC deaths per 1000 30-year-old individuals with cystic fibrosis who have not had a transplant. Among those who had a transplant, 22.3 CRC deaths per 1000 individuals were predicted to die from CRC ( Table 1) . The recommended US CRC screening strategy was estimated to prevent more than 73% of the CRC deaths among the US general population, 66% of CRC deaths among individuals with cystic fibrosis, and 39% of individuals with cystic fibrosis post-transplant. However, only 22% of individuals who received a transplant and 36% of those who did not were predicted to survive in the model until age 50, thereby meeting the age requirement to participate in this screening strategy ( Figure 2 ).
The costs and benefits of all simulated screening strategies for transplant and non-transplant individuals with cystic fibrosis were investigated (Supplementary Tables 3-6 ) and strategy-specific efficient frontiers are reported in Figure 3 . Among the efficient colonoscopy screening strategies, LYG from screening varied from 29 to 57 (per 1000 individuals 30 years of age) for non-transplant and from 28 to 64 for transplant cystic fibrosis patients. Higher benefits were associated with colonoscopy screening every 3 years from age 30 to 75, while the lower values for LYG for individuals with cystic fibrosis with and without organ transplant were observed, respectively, screening with once-lifetime colonoscopy at age 50 and 10-yearly colonoscopy from age 45 to 55.
For non-transplant individuals with cystic fibrosis, when only colonoscopy was considered as a screening test, the optimal colonoscopy strategy was 1 screen every 5 years from 40 to 75 years of age with an ICER of $84,000 per LYG ( Table 2 ). This strategy predicted 25 CRC cases and 4 CRC deaths to occur, equating to a reduction of 52% in CRC incidence and 79% for CRC mortality ( Table 2 ). Among transplanted cystic fibrosis patients, colonoscopy screening repeated every 3 years between ages 35 and 55 was optimal, preventing 82% of CRC mortality (ICER of $71,000 per LYG) compared with no screening (Table 3) .
When both FIT and colonoscopy screening strategies were jointly modeled (Supplementary analysis), the optimal screening strategy was annual FIT between age 35 and 75 years with an ICER of $47,000 per LYG (Table 2) for nontransplant individuals with cystic fibrosis. When compared with no screening, it could prevent 31% of CRC cases and 78% of the CRC deaths (16 CRC cases and 15 deaths per 1,000). FIT was also cost-effective for cystic fibrosis individuals who had undergone organ transplant with annual FIT between ages 30 and 60, achieving a reduction in CRC incidence of 20% and mortality of 77% with an ICER of $86,000 per LYG (Table 3) . LYG from screening were discounted (3%).
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Sensitivity Analyses
For many of the sensitivity analyses, the optimal screening strategy remained the same as the base case (Table 4 ). For non-transplant individuals with cystic fibrosis, the optimal age to stop colonoscopy screening was sensitive to our assumptions for higher all-cause mortality in older ages (55 years) or increased risk of cardiovascular complications (70 years). A colonoscopy screening interval of every 3 years was more optimal when adenoma dwell time was reduced and CRC risk was increased with more proximal adenoma location. Higher costs for colonoscopy (more time required for patients to be prepared for colonoscopy and to recover from its complications) resulted in a later age to start screening (45 years). When all strategies were investigated (Supplementary analysis), FIT start age was earlier (30 years) when adenoma dwell time was shortened and CRC risk was increased. A reduction in specificity and sensitivity of FIT increased the age of starting screening to 40 years. FIT screening should stop at age 60, when higher overall mortality was assumed among individuals with cystic fibrosis in older ages. FIT was not cost-effective when a biennial interval was considered.
Among transplant cystic fibrosis patients, less intense colonoscopy screening (every 5 years) was optimal when higher patient time costs were considered. For individuals with cystic fibrosis who had an organ transplant before age 30, colonoscopy screening was optimal from 30 years. However, optimal screening interval varied according to the age at organ transplant: every 10 years up to age 55 for those with transplantation at age 20; and every 5 years up to age 55 for those who had a transplant at age 25. When we assumed that older individuals with cystic fibrosis who had an organ transplant ( 50 years) had the same overall mortality as the non-transplant, the age to stop screening increased to 60 years of age. Considering all screening strategies (Supplementary analysis), FIT screening was not considered cost-effective when there was an increased CRC risk (45-fold), a shorter adenoma dwell time, biennial FIT, lower FIT sensitivity and specificity, and when the same age-specific mortality of non-transplant cystic fibrosis individuals (for those older than 50 years) were assumed for transplant cystic fibrosis patients. Optimal screening strategies among these individuals also varied according the age of organ transplant: FIT screening should start at age 25 when individuals with cystic fibrosis underwent transplantation at age 20 or 25 years.
Discussion
Recent studies have highlighted the necessity of tailored CRC screening for individuals with cystic fibrosis, reporting that these individuals have an increased risk of CRC compared with the average population. [5] [6] [7] [8] Using an established micro-simulation model, adjusted for the Efficient frontiers with efficient screening strategies for non-transplant cystic fibrosis and transplant cystic fibrosis patients. Total costs and LYG from screening were discounted (3% discounting rate) and 100% adherence was assumed for screening, diagnostic, and surveillance test. Optimal screening strategies are labelled and indicated by arrows. B, optimal strategy is the same of the base case; COL, colonoscopy; FIT, fecal immunochemical test; (n), screening interval; CF, cystic fibrosis. characteristics of cystic fibrosis populations, we found that the recommended US CRC screening strategy for the general population was not optimal for individuals with cystic fibrosis. A greater reduction in CRC mortality could be achieved if screening started before age 50 in both individuals who have and have not received an organ transplantation. Colonoscopy every 5 years starting at age 40 in individuals with cystic fibrosis who have not received a transplant was shown, in our study, to significantly improve LYG and CRC mortality at an acceptable cost (ICER of $84,000 per LYG). Our cost-effectiveness analysis suggests, for cystic fibrosis patients who underwent organ transplantation, more intensive colonoscopy screening starting at ages 30 (transplant at age 20 or 25) or 35 (transplant at age 30), through to age 55. The optimal screening interval varied according to age at organ transplant and patient time costs. The model also suggested that screening with FIT could be more cost-effective than colonoscopy (Supplementary analysis), but specific evidence of its performance in the cystic fibrosis population is required before considering this screening modality.
Despite the lower life-expectancy reported in cystic fibrosis population, the model suggests -especially for those who have not undergone organ transplantation -that screening should be repeated until age 75 years. Few individuals with cystic fibrosis currently reach this age, but once they survive to a certain age (ie, 65-70) their excess risk of dying compared with the general population becomes smaller and a death from CRC becomes more likely. Thus, screening is effective until age 75. However, the model was adjusted to reflect data on individuals with cystic fibrosis provided by the fibrosis Foundation Patient Registry, which contains only a very small number of individuals at older ages. Moreover, a previous study has shown that some death dates were missing in the fibrosis Foundation Patient Registry, especially for individuals with cystic fibrosis older than 45 years, when compared with national vital statistics. 45 Therefore, the model results on the age to stop screening could be less robust than those obtained on the age to start screening. A specific sensitivity analysis, carried out assuming a higher overall mortality in cystic fibrosis long-term survivors as reported by Nick et al in Colorado, 45 confirmed this hypothesis (Table 4) . This potentially incomplete ascertainment of outcomes may also affect estimates for CRC incidence. In that case, we would have underestimated the risk of CRC and the optimal colonoscopy screening strategy would be even more intensive than the base case: colonoscopy screening should start at age 40 and repeated every 3 years.
At the same time, our model suggests to screen individuals with cystic fibrosis who have had an organ transplant up to age 55. This difference is mainly related to the higher CRC risk seen in cystic fibrosis individuals after transplantation. Performing our analysis on transplant cystic fibrosis individuals (assuming transplant at age 30 years), the model predicted that all these patients developed 1 or more adenomas before age 55 and, therefore, entered colonoscopy surveillance rather than attending subsequent screening rounds. As a result, outcomes of similar strategies with different ages to stop screening, above age 60, were the same (Supplementary Tables 5-6 ). Although individuals with cystic fibrosis had a more frequent adenoma onset after organ transplant, the increase in CRC incidence was not as immediate, potentially because of the lag-time in the progression between adenoma and CRC. 46 This was shown in our analysis for starting screening age in transplant cystic fibrosis patients that underwent organ transplant at age 30.
Specific screening recommendations already exist for several groups of individuals at higher risk of CRC: individuals with family history of CRC (first-degree relative) are recommended to undergo colonoscopy every 5-10 years, starting at age 40.
47 Individuals with Lynch syndrome should undergo colonoscopy every 1-2 years starting at age 20-25 years. 48 CRC risk in the cystic fibrosis population falls somewhere between the risk of these different groups, with the risk in transplant patients (30-fold increase compared with general population) 6 being higher than Lynch syndrome patients. 49 This indicates that individuals with cystic fibrosis should potentially have similar recommendations as these other high-risk groups. However, it is also necessary to consider the different life expectancy of individuals with cystic fibrosis compared with individuals in other high-risk groups because this may influence the balance between the harms and benefits of screening. This effect may be seen in Table 1 . Although patients with cystic fibrosis have an up to 30-fold increased CRC risk compared with average US individuals, CRC deaths predicted among them were less than reported for the US general population (19.1 and 22.3 vs 27.8 per 1000) because of their more elevated 'other cause' mortality (70% of the deaths in cystic fibrosis individuals are related to cardiorespiratory causes). 4 While early diagnosis may prevent a CRC death, screening may result in an over-diagnosis because of cystic fibrosis-related competing causes of death, and can incur in additional costs from screening and treatment. Thus, CRC screening guidelines for the other high-risk group cannot be simply generalized to individuals with cystic fibrosis. This may explain why, unlike for individuals with Lynch syndrome, more intensive screening strategies were not found to be cost-effective for the cystic fibrosis population.
Several studies have recently highlighted the necessity of tailored CRC screening for the cystic fibrosis population [5] [6] [7] [8] and, to our knowledge, this is the first study to assess the cost-effectiveness of CRC screening in these individuals. The results of this formal decision analysis, which was requested by the Cystic Fibrosis Foundation and cystic Fibrosis Foundation and Cystic Fibrosis CRC Screening Task Force to inform the cystic fibrosis CRC screening consensus recommendations 19 have provided important suggestions for clinicians, researchers, and policy makers who were tasked with developing an appropriate CRC screening policy for people with cystic fibrosis in the US. However, the findings of this study should be interpreted with caution considering the following limitations. First, we did not model the natural history of CRC separately for men and women. Epidemiological studies among cystic fibrosis patients report gender differences: women experience a lower risk of developing CRC 6 and lower life-expectancy 50 than men. Considering these differences, a less intensive CRC screening strategy could be optimal for women with cystic fibrosis. However, there is little data on CRC incidence and mortality in these patients and even less is stratified by gender, meaning this differentiation is not yet feasible. Second, our analysis was not stratified for pulmonary function (an important clinical indicator of the health of individuals with cystic fibrosis). Although Niccum and colleagues 8 only considered cystic fibrosis patients with predicted FEV1 40% eligible to CRC screening, the available data for individuals with cystic fibrosis did not permit this additional model stratification. The most recent Cystic Fibrosis Patient Registry Annual Report showed that up to 75% of individuals with cystic fibrosis aged 40 years had a predicted FEV1 40%. 4 If screening was limited to this subset of individuals, the balance between harms and benefits of screening in individuals with cystic fibrosis would become more favorable.
Furthermore, we assumed that adenomas in persons with cystic fibrosis could arise following the same localization-specific distribution observed in autopsy studies for the general population [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and with the same increased risk -7-fold compared with the general population -in both the colon and rectum. Although Maisonneuve and colleagues 6 reported that CRC cases were mainly located in the colon of individuals with cystic fibrosis (26 out 28 cases), a direct calibration of the adenoma localization-specific onset distribution was not possible because limited data is currently available. To address this, we performed a sensitivity analysis to assess the effects of assuming a different localization-specific distribution for adenoma onset in people with cystic fibrosis and screening strategy outcomes were not sensitive to this assumption (Table 4) .
Several factors may cause the higher risk of CRC in the cystic fibrosis population, but information about the rationale of this increased risk remains unclear. We assumed that the higher risk of CRC shown in the cystic fibrosis population was because of a more frequent adenoma onset. This assumption was validated for non-transplant patients, but not for individuals with cystic fibrosis who had an organ transplant (Supplementary Figure 3) . A shorter adenoma dwell time may also play a role in the progression from adenoma to CRC. To investigate this, we performed a specific sensitivity analysis assuming a shorter dwell time (50% reduced, faster adenoma progression) and more elevated adenoma onset (16-fold increased risk) for transplant cystic fibrosis patients. The results of this sensitivity analysis were validated with adenoma detection rates observed in an observational study of cystic fibrosis patients undergoing colonoscopy screening (Supplementary Figure 3) . 8 However, this analysis revealed that our cost-effectiveness outcomes were not sensitive to this assumption. Our model does not explicitly describe adenoma histology and that may explain the lower simulated rates of colonoscopy-detected advanced adenomas (Supplementary Figure 3) .
In our study, assumptions on colonoscopy performance, complications, polypectomy safety, costs (including sedation costs), and adverse events of bowel preparation were informed by data from the general population and the Medicare population 40 because specific empirical data for the cystic fibrosis population were not available. For colonoscopy performance, this assumption seems reasonable because model-predicted adenoma detection rates were close to observed (Supplementary Figure 3) . However, it may be reasonable to assume that risk of complications and/or inadequate bowel preparation is higher in people with cystic fibrosis compared with the general population. Also, the more intensive and extended bowel preparation regimens for individuals with cystic fibrosis and additional colonoscopy investigations because of inadequate bowel preparation could lead to a further increase in adverse events. To address this concern, we performed specific sensitivity analyses on colonoscopy performance and rate of complications (especially for cardiovascular adverse events, including respiratory arrest, Supplementary Tables 7 and 8) .
Results of these analyses showed that the optimal screening starting ages and intervals were not sensitive to changes in these assumptions (Table 4) .
The feasibility of colonoscopy in individuals with cystic fibrosis and its capacity to early detect CRC and adenomas in these individuals was suggested by the findings of a small observational study conducted in Minnesota. 8 Moreover, colonoscopy is the screening test of choice for higher-risk groups. 47, 48 We therefore focused our main analysis and interpretation of our results on this screening modality. However, given the potential burden of colonoscopy and colonoscopy preparation to the cystic fibrosis patient, we believe it was pertinent to also consider FIT as a possible and hypothetically adequate alternative. As such, we performed a specific supplementary analysis including annual FIT screening. We found that this screening modality was cost-effective and optimal among individuals with cystic fibrosis. However, because information on FIT characteristics in this population is lacking, the analysis was performed using FIT characteristics from the general population. 37 In individuals with cystic fibrosis, the presence of blood in feces could be related to several gastrointestinal disorders, 51 which could affect the effectiveness and cost-effectiveness of FIT screening in the cystic fibrosis population. Sensitivity analyses revealed that our results on cost-effectiveness of FIT depend on screening intensity and the test characteristics as assumed in this analysis, especially for post-transplant cystic fibrosis patients. Hence, before considering FIT as the preferred screening modality, FIT performance must be tested in the cystic fibrosis population to better explore its effectiveness in early detection of CRC and adenomas among this population. If future studies confirm that FIT in individuals with cystic fibrosis performs as well as or better than we assumed in our sensitivity analyses, FIT may be considered an attractive screening option for this population. In the meantime, FIT could be considered for those not willing to undergo colonoscopy.
Despite its limitations, this study has important clinical and policy implications. This study indicates that there is benefit to earlier CRC screening in the cystic fibrosis population and can be done at acceptable costs. The findings of this analysis support clinicians, researchers, and policy makers who aim to define a tailored CRC screening for individuals with cystic fibrosis in the US. Meanwhile, outcomes of screening in individuals with cystic fibrosis should be closely monitored to accumulate evidence on the performance and safety of CRC screening in these individuals. FIT characteristics were based on a large US-based study comparing multi-targeted stool DNA with FIT in a screening setting. 34 c Specificity for colonoscopy is therefore based on an adenoma prevalence study of patients undergoing screening colonoscopy. 
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MISCAN-Colon Model Description (Model)
General Model Structure MISCAN-Colon is a stochastic microsimulation model for CRC that is useful in explaining and predicting trends in CRC incidence and mortality rates and to assess the effects and costs of primary prevention and screening for CRC. 17 The model simulates the life history of each person at an individual level, rather than as proportions of a cohort. For that reason, the model allows the time dependence between future and past state transitions. However, in contrast to most traditional Markov models, MISCAN-Colon does not use yearly transition probabilities, rather it generates durations in states. This solution increases the model flexibility and computational performance. In addition, the model simulates sequences of events by drawing from distribution of probability or durations, rather than using fixed values. Hence, the results of the model are subject to random variation.
MISCAN-Colon consists of 3 modules: a demography module, natural history module, and screening module.
The Demography Module
The MISCAN-Colon model draws a date of birth and a date of no-CRC death for each individual simulated, using birth and life tables (representative of the population under consideration). The model restricts the maximum age a person can achieve to 100 years.
The Natural History Module
As each simulated person ages, 1 or more adenomas may develop (Supplementary Figure 5) . These adenomas can be either progressive or non-progressive and both can grow in size from small (<5 mm) to medium (6-9 mm) and then to large (> 10 mm). Only progressive adenomas can develop into preclinical cancer, which may progress through stages I to IV. However, during each stage, CRC may be diagnosed because of symptoms. After CRC clinical diagnosis, survival time is simulated using age-, stage-, and localization-specific survival estimates for clinically diagnosed CRC based on a study published by Rutter and colleagues. 19 For synchronous CRCs, survival is based on the most advance cancer. The date of death for CRC patients is the earliest simulated date of death (because of CRC or another cause).
The probability of adenoma onset differs among the individuals and depends on the person's age and risk index. For that reason, most persons do not develop adenomas and some others develop many. The distribution of adenoma over the colon and rectum was assumed equal to the distribution of cancer cases seen in SEER before the introduction of screening. 38 The personal risk index and the age-specific onset of adenomas were calibrated to adenoma prevalence data obtained in several autopsy studies (Supplementary Figure 2) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 38 Furthermore, the age-specific probability of adenoma progressivity and the age-or localization-specific transition between preclinical and clinical cancer stages were calibrated to SEER data on age-, stage-, and localization-specific incidence of CRC in pre-screening years (ie, 1975-1979 , Supplementary  Figure 1) . 38 The average duration of the preclinical cancer stages were calibrated according to data obtained from randomized, controlled trials (RCTs) evaluating screening using guaiac fecal occult blood tests. 10, 11, 14 The average duration between adenoma onset and progression into preclinical cancer (adenoma dwell time) was calibrated to the data on interval cancer seen in a sigmoidoscopy screening RCT. 9 Furthermore, we assumed: an equal overall dwell time for adenoma developing into cancer from medium (30% of all CRCs) and from large-size adenomas (70% of all CRCs); exponential distribution for all duration in the adenoma and preclinical cancer phases; perfect correlation for the durations within adenoma and preclinical cancer (quicker growing from small adenoma and mediumsized adenoma, quicker developing into preclinical CRC); absence of correlation between durations in the adenoma phase and duration in the preclinical cancer phase.
The Screening Module
Screening will modify some of the simulated life histories. Some cancer cases will be prevented by the detection and removal of adenomas or by detection in an earlier stage (favorable survival). As seen in RCTs on guaiac fecal occult blood testing, the stage-specific survival of screen-detected CRC was more favorable compared with clinically detected CRC, even after the lead-time bias correction. 12 Hence, we assigned those screen-detected cancer cases -that without screening would have been clinically detected in the same stage -a survival corresponding to a cancer that is 1 stage less progressive. The only exceptions were screen-detected stage IV cancer cases: we assigned the survival of a clinically diagnosed stage IV cancer. Furthermore, together with the positive effects of screening, we also modelled overdiagnosis, overtreatment, and colonoscopy-related complications. 36 
Integrating Modules
For each person simulated, a date of birth and a date of no-CRC death (a lifetime history without adenoma or CRC) are generated from the demography module. In patient A in Supplementary Figure 6 , the natural history module generates an adenoma. This adenoma progresses into preclinical cancer (diagnosed as stage II CRC because of symptoms) and results in CRC death before non-CRC death would have occurred. However, in the screening module, a screening examination is introduced: the adenoma is detected, removed, and the CRC death prevented. The positive effect of the screening intervention is indicated by the green arrow and represents the increased LYG for this patient because of screening. Another example is patient B, who develops an adenoma that would never have been diagnosed in a no-screening scenario. However, during the screening examination, CRC is screen-detected in stage I and -for this patient -screening results in overdiagnosis and overtreatment of CRC (no LYG, but only additional LYs with CRC care).
Results for US General Population (Included in this Study)
According to the MISCAN-Colon model, up to 73% of CRC deaths may be avoided by introducing CRC screening in the US general population (Table 1) . While this result may appear elevated considering the findings of several RCTs, 9, [15] [16] [17] it is in accordance with assumptions made in our analysis. We investigated the impact of screening in the entire colorectum with 100% adherence to screening (in each screening round) and surveillance tests. The RCTs mainly investigated the effect of screening on the left colon (once-only flexible sigmoidoscopy), reporting a 22%-31% reduction in CRC mortality with a compliance ranging from 58% to 71%. 9, 15, 17 Schoen et al reported a 50% reduction in distal CRC mortality in those invited to flexible sigmoidoscopy (54% of adherence in those invited to repeat screening every 5 or 3 years). 16 Furthermore, the MISCAN-Colon model is calibrated and validated against data from the UK flexible sigmoidoscopy screening trial. 34 Supplementary Figure 5 . The general model structure of the MISCAN-Colon model.
